Study summary
Across trials, early treatment cut progression risk by 60% and death risk by 45%
0.40hazard ratio for progression or death with early treatment
What was tested
A pooled analysis of randomized trials comparing early treatment with observation for smoldering multiple myeloma.
What they found
- Early treatment cut the risk of progression or death by 60% (hazard ratio 0.40).
- Two trials with mature data showed 45% lower risk of death.
- Serious side effects were about 3.5 times more likely with treatment.
What it means
Supports early treatment for high-risk people, with careful attention to side effects.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.